LL12 Myoviridae Bacteriophage.
A precision antimicrobial phage that targets specific harmful bacteria in your gut. Targets and eliminates specific harmful bacteria in the gut as part of a phage cocktail.
Reviewed March 2026
- Category
- General
- Also filed under
- Targeted bacterial eliminationMicrobiome preservationPrecision antimicrobial
What LL12 Myoviridae Bacteriophage is, and what it does.
- Does it work
- Part of an interesting category, but zero strain-specific clinical evidence.
- How much to take
- Measured in PFU as part of a cocktail. Follow the product label.
- Time to feel it
- No trial has timed this strain on its own. Shifts from phage preparations are measured by stool sampling over two to four weeks rather than felt.
- The first dose
- Day one is quiet. A phage acts only where its target bacterium is present, and that shows up as a shift in stool bacterial counts over the following weeks.
- With regular use
- Possible microbiome shifts over weeks. No specific data.
- How well tolerated
- Well tolerated. Phages are naturally present in your gut and can't infect human cells.
- How it feels
- No sensation comes with it. Any change registers in the bacterial counts of a stool test over weeks, and for some people as steadier digestive comfort alongside the rest of a cocktail.
- The overlooked benefit
- Phage potency is declared in plaque-forming units against a named host bacterium, not in milligrams, so the weight on a label says nothing about how much active phage is there.
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- Selective bacterial targeting
- Gut health benefit
Questions people ask about LL12 Myoviridae Bacteriophage.
- What makes LL12 different from other Myoviridae phages?
- It targets different bacterial strains. Each phage in a cocktail covers specific pathogens. LL12's exact targets aren't publicly detailed.
- Can phages survive stomach acid?
- Many can't, which is why quality phage supplements use acid-resistant capsules for delivery.
- Are phage supplements regulated?
- In the US, they're sold as dietary supplements under DSHEA. They don't need FDA pre-approval, but they must be safe and properly labeled.
- Why take a phage cocktail instead of one phage?
- Different phages target different bacteria. A cocktail covers more pathogens and makes it harder for bacteria to develop resistance.
- Will this interact with my medications?
- Phages only interact with bacteria, not human biology or drugs. No known medication interactions.
- How long should I take phage supplements?
- No established protocol. Most products suggest ongoing use, but there's no clinical guidance on duration.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
LL12 is a lytic phage directed at specific Escherichia coli strains and does not infect the lactic acid bacteria delivered alongside it. Removing the target population opens nutrients and attachment sites for the co dosed strains.
The phage receptor is a coliform surface structure that lactobacilli do not carry, so the delivered strain passes through unaffected. The pairing narrows competition in the same gut niche while leaving the probiotic intact.
Lytic coliform phages have a narrow host range and cannot adsorb to Lactobacillus rhamnosus, so the two can share a capsule. The phage acts only on the competing coliform population in the same environment.
Phage host range is defined by the surface receptors a phage can adsorb to, and a phage raised on a Gram-negative host does not adsorb to a Gram-positive Bifidobacterium. That specificity is why a phage preparation and a bifidobacterial probiotic are formulated together. Whether the pairing changes anything measurable in the gut community is not established.
The same receptor-specificity argument applies: a phage with a narrow Gram-negative host range leaves this species untouched. Product design pairs the two so the phage acts on one part of the community while the probiotic adds another. The rationale is microbiological rather than clinical.
Commercial phage blends are selected against target hosts, and lactobacilli are ordinarily outside that host range. Confirming non-susceptibility of the specific probiotic strain is a manufacturing check rather than an assumption, because lactobacilli do have their own phages. Where the check is done, the two can share a capsule.
Bacteriophages infect bacteria only. A yeast probiotic cannot be a host, so there is no possibility of phage predation on it. The pairing is mechanically compatible. Any joint effect on the gut community is a separate question.
A phage acts by removing specific host bacteria, which frees a niche. A fermentable fructan supplies substrate that determines which organisms fill it. The two act at opposite ends of the same ecological process. This is ecological reasoning, and no combination study is cited.
Short-chain fructans are fermented rapidly in the proximal colon by bifidobacteria and lactobacilli. Pairing them with a narrowly targeted phage is a subtract-and-feed design. The mechanism is plausible. The outcome in a human gut has not been measured here.
Galactooligosaccharides are selectively fermented by bifidobacteria and shift community composition on their own. A phage component targets a different member of the community. The two act by unrelated mechanisms in one formula.
Resistant starch escapes small intestinal digestion and is fermented distally by starch-degrading colonic bacteria, producing butyrate. A phage preparation changes which organisms are present to do that fermenting. The combined result depends on the starting community.
This is a low-viscosity fermentable fibre used where bulk and gas are the limiting complaints. It supplies substrate along the colon while a phage acts on specific hosts. Two unrelated mechanisms in the same product.
Butyrate is the main energy substrate for colonocytes and is normally produced by fermentation in the colon. Supplying it directly bypasses the microbial step that a phage preparation is intended to influence. The two address the same system from different ends.
Oat beta-glucan is a viscous, fermentable fibre that feeds colonic bacteria and slows small intestinal transit. Slower transit changes the contact time between a phage particle and its host population. The interaction is plausible and unquantified.
Lactoferrin sequesters free iron, which many Gram-negative bacteria need, and its N-terminal region interacts with lipopolysaccharide on the outer membrane. A phage acts on the same class of organism by adsorbing to specific surface receptors. The two act on overlapping targets by unrelated means.
Bovine colostrum supplies immunoglobulins and oligosaccharides that act on gut bacteria and on the mucosal surface. A phage preparation works by host-specific lysis. Combining them stacks unrelated mechanisms. No combination data is cited.
Glutamine is a preferred fuel for enterocytes and supports normal intestinal epithelial turnover. It has nothing to do with phage biology, which is exactly why the two are combined in gut formulas. The pairing is formulation design rather than a demonstrated interaction.
Zinc carnosine is used for its adherence to the gastric and intestinal mucosa and its role in normal epithelial repair. It works on the host side while a phage works on the bacterial side. Different targets, one formula.
Phage capsids are protein and lose infectivity at low gastric pH, which is why phage preparations are given with buffering or in an acid-resistant capsule. Bicarbonate raises gastric pH transiently and is used for that purpose in phage handling. The step is a delivery measure, not an activity of the phage itself.
Phage particles are built from protein subunits, so acid-stable proteases in a digestive enzyme blend can degrade capsid and tail structures. Co-formulating a protease with a phage preparation works against the phage surviving to the colon. Separating them is the straightforward handling.
Pepsin is active at gastric pH and cleaves protein, and a phage particle is a protein shell around a DNA genome. Adding pepsin, or anything that keeps the stomach strongly acidic, works against phage survival in transit. This is a delivery consideration rather than a claim about either ingredient.
Activated charcoal has an enormous adsorptive surface and binds proteins and particles non-selectively. Phage particles are in that size and composition range. Taking the two together works against the phage reaching its target, so spacing them is the sensible handling.
Clay minerals adsorb viruses and proteins onto their charged layered surfaces, a property documented in water treatment and soil virology. A phage preparation taken with a clay binder is likely to be partly adsorbed. Separating the doses avoids the question.
Talk to a doctor before taking LL12 Myoviridae Bacteriophage if any of these apply to you: Minimal clinical data for supplementation, Narrow specificity. These are flags to check first, not effects LL12 Myoviridae Bacteriophage is known to cause.
Not medical advice. Show the label to your pharmacist.What LL12 Myoviridae Bacteriophage actually does.
Myoviridae are tailed DNA phages with a spring-like tail: on contact with a bacterium the sheath contracts and drives a tube through the cell's envelope to deliver the genes.
Which bacteria a phage can infect is set by its tail fibres, which bind specific surface structures like sugars, membrane proteins or pili. A cell without the matching receptor cannot be infected at all.
That receptor requirement is why a phage acts on a narrow set of bacterial strains, unlike a broad-spectrum antibacterial agent that hits many genera at once.
In the lytic cycle the injected genes turn the bacterium into a phage factory and then break its wall from the inside to release the new particles. In the lysogenic cycle the genes instead slip into the host's chromosome and copy along with it.
Where LL12 Myoviridae Bacteriophage comes from.
The phage is first found in the wild, usually in water or sewage where the bacteria it infects live, and then grown by feeding it a tank of those bacteria until they burst. What is left is filtered and washed until only phage particles remain, counted by a plaque test, and freeze-dried into a powder.
Produced by a cultured organism rather than harvested. The strain is selected and the conditions are controlled, so batches sit closer together than a field crop.
Phages for supplement use are isolated from environments where their hosts live, commonly sewage, surface water or soil, then plaque-purified against a defined bacterial host strain. That host strain, grown in a fermenter, is the substrate for everything that follows.
The purified phage is added to an actively growing host culture at a controlled multiplicity of infection. The culture is lysed by the phage itself, releasing a lysate containing phage particles along with host cell debris, proteins and nucleic acids.
The lysate is clarified by centrifugation and depth filtration, then concentrated and washed by tangential flow filtration. Where the host is Gram-negative, dedicated endotoxin removal steps follow, since lipopolysaccharide from the lysed host is the main residual contaminant of concern.
Potency is measured as plaque-forming units per gram on the defined host strain, and identity is confirmed by genome sequencing, which also checks that the isolate is lytic and carries no toxin or resistance genes.
The concentrate is freeze-dried with a cryoprotectant, blended onto a carrier to a target titre and packed with a desiccant, usually in a moisture-barrier capsule or sachet.
Getting LL12 Myoviridae Bacteriophage from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- In a 4-week randomised, double-blind, placebo-controlled trial in 68 healthy adults, adding a bacteriophage blend containing LL12 to a Bifidobacterium animalis subsp. lactis probiotic showed a within-group improvement in a self-reported gut symptom score (p = 0.01) and a larger rise in Lactobacillus and short-chain fatty acid producing bacteria than the probiotic alone.Randomised trial. Grubb et al., 2020 (Nutrients). PMID 32824480 ↗
- A review of how bacteriophages shape the gut microbial community describes phage-host dynamics, lysogeny and the effect of predation on bacterial population structure. It covers phages as a class and does not report results for any single commercial phage preparation.Narrative review. Mahmud et al., 2024 (Gut Microbes). PMID 39167701 ↗
- A review of bacteriophages used in food supplements obtained from natural sources describes how such preparations are sourced and characterised and what has been reported for them. It is a descriptive review rather than a trial of a defined product.Narrative review. Kiani et al., 2020 (Acta Biomedica). PMID 33170168 ↗
These are the studies our verdict leans on, chosen from the 7 we read for LL12 Myoviridae Bacteriophage. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.
